CSIMarket Company Name, Ticker, Industry, else..
 
Peak Bio Inc   (NONE: PKBO)
Other Ticker:  
 
 
Price: $0.0225 $-0.05 -67.857%
Day's High: $0.0236 Week Perf: -79.55 %
Day's Low: $ 0.02 30 Day Perf: 341.18 %
Volume (M): 66 52 Wk High: $ 0.18
Volume (M$): $ 1 52 Wk Avg: $0.05
Open: $0.02 52 Wk Low: $0.00



 Market Capitalization (Millions $) 1
 Shares Outstanding (Millions) 28
 Employees -
 Revenues (TTM) (Millions $) -
 Net Income (TTM) (Millions $) -3
 Cash Flow (TTM) (Millions $) 1
 Capital Exp. (TTM) (Millions $) 0

Peak Bio Inc
Peak Bio Inc is a biotechnology company that focuses on developing innovative therapeutic solutions for various medical conditions. The company is driven by a mission to improve global health outcomes and enhance quality of life for patients through cutting-edge research and development efforts. Their pipeline includes a range of novel drug candidates targeting cancer, neurodegenerative disorders, and rare diseases, among others. Peak Bio Inc is known for its interdisciplinary approach, combining expertise in biology, chemistry, and pharmacology to provide effective and safe treatments. With a strong commitment to scientific excellence, the company has gained recognition within the biotech industry and has established strategic collaborations with leading academic institutions and pharmaceutical companies.


   Company Address: 4900 Hopyard Road., Suite 100 Pleasanton 94588 CA
   Company Phone Number: 463-4800   Stock Exchange / Ticker: NONE PKBO


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
AMGN   -3.04%    
BIIB        2.99% 
EXEL        3.4% 
GILD        0.88% 
HALO        1.04% 
MRNA   -1.61%    
• View Complete Report
   



Peak Bio Inc

Breaking down third quarter of 2024 numbers, PKBOs' saw revenue were unaffected from the similar period a year ago

Analyzing Peak Bio Inc: A Look at Current Stock Performance and Financial ResultsCurrent Stock PerformanceAs of now, Peak Bio Inc appears to be facing significant challenges in the market, with its stock trading at -39.7% below its 52-week average. This sharp decline raises questions about investor sentiment and company performance, especially in light of its recent financial results. Positive EPS Growth in Q3 2024Despite the struggles in stock performance, Peak Bio Inc reported an impressive turnaround in earnings for the third quarter of 2024. The company achieved an earnings per share (EPS) of $0.06, a substantial increase of 500% compared to the $0.01 EPS from the same quarter last year. Additionally, this represents a positive shift from the previous reporting period where the company reported a loss of $-0.09 per share. This remarkable EPS growth indicates that the company is beginning to capitalize on its operations and may be finding effective strategies to improve profitability. However, it is crucial to consider the other financial metrics alongside this positive development. Stable Revenue Amid EPS SurgeInterestingly, the revenue for Peak Bio Inc remained stagnant at $0.00 million for the third quarter of 2024, which is a significant drop from $0.28 million in the same period last year. This raises critical questions about the sustainability of the growth in EPS. While the negative revenue indicates that the company might be undergoing operational challenges, the strong EPS suggests that Peak Bio has managed to cut costs or improve its net income effectively.This contradiction leads us to wonder how Peak Bio plans to address its revenue challenges moving forward. It may need to reconsider its business operations or identify new revenue streams to ensure that it harnesses the positive momentum in EPS growth.
Merger and Acquisition

Revolutionizing Targeted Therapeutics: Akari Therapeutics and Peak Bio Unveil Portfolio Prioritization Plan for Post-Merger Entity

Published Wed, May 1 2024 12:01 PM UTC

Akari Therapeutics and Peak Bio Join Forces in Strategic Merger, Prioritizing ADC Technology and GA Program
BOSTON and PLEASANTON, Calif., May 01, 2024 - Akari Therapeutics, Plc (Nasdaq: AKTX, Akari) and Peak Bio Inc. (OTC: PKBO, Peak) have recently announced the successful completion of a joint portfolio prioritization review. This marks a significant milestone in their...
Peak Bio Inc

Peak Bio Inc: Biotech & Pharma Company Shows Resilience Despite Operating Deficit in Q2 2023

Exciting Prospects in the Biotechnology & Pharmaceuticals Sector
The stock market is always full of surprises, and it appears that the Biotechnology & Pharmaceuticals sector has been attracting a great deal of attention lately. While the big players continue to dominate the market, a wave of smaller businesses is also making their mark. One such company, PKBO, has recently reported some interesting figures that could impact its future performance.
For the second quarter of 2023, PKBO announced an operating deficit of $-2.670212 million. While this may seem like a cause for concern, it is important to consider the context. To better understand the significance of these numbers, it is worth comparing them to the second quarter of 2022, when the operating deficit stood at $-0.798156 million. This indicates that PKBO has faced some challenges but has not experienced a drastic decline in its financial performance.
Peak Bio Inc

Peak Bio Inc Stuns with Impressive Q1 Revenue of $0.013854 Million for 2023; Sees Flourishing Growth in Biotech Sector

Exciting Times Ahead: Peak Bio Inc's Revenue Shows Promising Growth in the Biotechnology & Pharmaceuticals Sector
The world of biotechnology and pharmaceuticals continues to hold immense potential for investors, offering lucrative opportunities to those who wisely choose their stocks. In this exhilarating realm, one company has recently caught our attention: Peak Bio Inc.
In its most recent financial report, Peak Bio Inc revealed an impressive revenue of $0.013854 million for the financial span closing on March 31, 2023. This figure not only demonstrates their consistent growth but also highlights their unwavering commitment to innovation and success in the biotech industry.









Help

About us

Advertise
CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2025 CSIMarket, Inc. All rights reserved.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com